Authors
Latest:
Future Management of Uveal MelanomaThe next steps in research investigating best practices using novel therapies such as tebentafusp as treatment for uveal melanoma.
Latest:
Dr Annie Im: How to Treat Acute Myeloid Leukemia in 2024Annie Im, MD, FASCO, University of Pittsburgh/UPMC Hillman Cancer Center, discusses the various modern approaches for the treatment of patients with acute myeloid leukemia.
Latest:
Dr Park on the Combo of Epacadostat and Chemoradiation in Advanced Rectal CancerHaeseong Park, MD, MPH, discusses the rationale for combining epacadostat with preoperative chemoradiation in locally advanced rectal cancer.
Latest:
Dr. Vunjak-Novakovic on the Clinical Need for Personalizing Cancer CareGordana Vunjak-Novakovic, PhD, BS, MS, discusses the clinical need for personalizing cancer care.
Latest:
Dr Jimenez Jimenez on the Clinical Implications of the ACCESS Trial in Hematological MalignanciesAntonio Martin Jimenez Jimenez, MD, discusses the clinical implications of PBSC from HLA-MMUD and PTCy for GVHD prophylaxis in hematological malignancies.
Latest:
Dr Richardson on the Safety of Upifitamab Rilsodotin in Platinum-Resistant Ovarian CancerDebra L. Richardson, MD, FACS, FACOG, discusses the safety profile of upifitamab rilsodotin in the phase 1/2 UPLIFT trial of patients with ovarian cancer.
Latest:
Dr. Mita on Treatment Selection in ER+, HER2- Breast CancerMonica M. Mita, MD, discusses treatment selection for patients with estrogen receptor–positive, HER2-negative breast cancer.
Latest:
Dr Popat on OS Outcomes With Amivantamab Plus Chemotherapy in EGFR-Mutated, Advanced NSCLCSanjay Popat, BSc, MBBS, FRCP, PhD, discusses OS data with amivantamab plus chemotherapy in EGFR-mutated, advanced NSCLC after progression on osimertinib.
Latest:
Dr Qian on Preclinical Data for a CXCR4 Partial Agonist Plus Anti–PD-1 Therapy in Gastric Cancer.Jin Qian, PhD, discusses preclinical findings for CXCR4 partial agonist in combination with anti–PD-1 therapy in advanced gastric cancer.
Latest:
Dr. Pakkala on Integrating Local Therapy into HER2+ Breast Cancer TreatmentSuchita Pakkala, MD, discusses ongoing efforts to integrate local therapy into HER2-positive breast cancer treatment.
Latest:
The Future of Metastatic and Unresectable Melanoma TreatmentThe panel concludes their discussion with a call for continued research and collaboration, emphasizing the need for more understanding of targeted therapies, monitoring tools like ctDNA, and ongoing development in the field of BRAF mutant melanoma treatment.
Latest:
ASCO GU 2022: Piecing Together Prostate Cancer Data With Drs. Tanya Dorff and Jathin BandariOncLive speaks with Drs. Tanya Dorff and Jathin Bandari on some exciting prostate cancer studies.
Latest:
Mount Sinai Researchers Discover How Early-Stage Breast Cancer Can Become a Silent Killer in Some PatientsMount Sinai researchers have discovered a previously unknown mechanism in which not-yet-malignant cells from early breast cancer tumors travel to other organs and, eventually, “turn on” and become metastatic breast cancer.
Latest:
Dr Singer on the Safety of Perioperative Nivolumab and Cabozantinib in RCCEric A. Singer, MD, discusses the safety of perioperative nivolumab and cabozantinib in patients with metastatic clear cell renal cell carcinoma.
Latest:
Advances in Targeted Therapy, Treatment Disparities Among Cancer Conference TalksTargeted therapy, genomics, and treatment disparities were among the topics that were presented by researchers from UCSF at the 2024 AACR conference.
Latest:
Dr. Mai on Barriers of Genetic Testing in CRCPhuong L. Mai, MD, discusses barriers of genetic testing in colorectal cancer.
Latest:
Creating the In-Person Experience on a Virtual PlatformThe coronavirus disease 2019 crisis has changed all aspects of medical education but perhaps altered clinical education most dramatically.
Latest:
Dr. Crown on the Investigation of Lapatinib Plus Chemotherapy in HER2+ Breast CancerJohn Crown, MB, BCh, BAO, BSc, MD, MBA, discusses the rationale for evaluating lapatinib (Tykerb) with standard trastuzumab/chemotherapy regimen in patients with HER2-positive breast cancer, as well as contextualizes results from a phase 2 trial.
Latest:
Women in Oncology: Self-Advocacy in a Busy FieldMelinda Butsch Kovacic, MPH, PhD; Elizabeth Shaughnessy, MD, PhD; Sandra L. Starnes, MD; and Susan E. Waltz, PhD, discuss the advice they would give to their younger selves and future female oncology professionals, knowing what they know now about the oncology field and their own career growth.
Latest:
Non-Pharmacologic Therapies for Pain Management in Patients With Cancer: Opportunities and ChallengesJanet Abrahm, MD, FACP, FAAHPM, reviews the standing of the role of integrative therapies in cancer care.
Latest:
Dr O'Cearbhaill on Results With Ubamatamab Plus Cemiplimab in Recurrent Ovarian CancerRoisin E. O'Cearbhaill, MD, discusses key findings from a phase 1/2 dose escalation study of ubamatamab plus cemiplimab in recurrent ovarian cancer.
Latest:
Charting the Course for Patients With High-Risk Colon Cancer: 3 Months Versus 6 MonthsIn 5 years, it is estimated that approximately 20% of patients with stage II disease and 35% with stage III disease will experience disease recurrence. These estimates highlight the need to pursue progress in adjuvant systemic therapy in order to decrease recurrence rates and improve survival.
Latest:
Considering Novel Therapy for HER2+ Metastatic Breast CancerA summary of sequencing therapy in the HER2+ metastatic breast cancer treatment paradigm followed by excitement for novel therapies under investigation.
Latest:
Dr. D’Souza on the Utilization of Monoclonal Antibodies and Immunomodulating Agents in AL AmyloidosisAnita D’Souza, MD, discusses the utilization of monoclonal antibodies and immunomodulating agents in patients with light chain amyloidosis.
Latest:
Dr Krause on GLP-1 Receptor Agonist Therapy in Endometrial CancerDanielle Krause, MD, discusses the effects of GLP-1 receptor agonist therapy in endometrial cancer.
Latest:
Important Considerations for Biomarker Testing in NSCLC at Key Points in Treatment JourneyThe biomarker testing landscape has evolved over the years, affecting how oncologists approach lung cancer.
Latest:
Primary Overall Survival Analysis of the Phase 3 Randomized ZUMA‑7 Study of Axicabtagene Ciloleucel Versus Standard-of-Care Therapy in Relapsed/Refractory Large B-Cell LymphomaJason R. Westin, MD, MS, FACP, presents the overall survival analysis from ZUMA-7, a phase 3 study investigating axicabtagene ciloleucel (axi-cel) versus standard-of-care therapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).
Latest:
Dr. Piliè on the Benefit of Second-Generation AR Inhibitors in Nonmetastatic CRPCPatrick Piliè, MD, discusses the benefit of second-generation androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer.
Latest:
Dr. Naqash and Dr. Chen on the Efficacy of Atezolizumab in Advanced Alveolar Soft Part SarcomaAbdul Rafeh Naqash, MD, and Alice Chen, MD, discuss their phase 2 trial evaluating the efficacy of atezolizumab in patients with advanced alveolar soft part sarcoma.
.jpg?fit=crop&auto=format)
